Semin Arthritis Rheu: Characteristics and outcomes of patients with diseased macroblastitis in the eye
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The study was designed to describe the characteristics and prognosis of patients with clottel arteritis (GCA)-related eye injuries at the time of diagnosisa retrospective single-center cohort study of 409 continuing GCA patients, 104 of which had visual symptoms at GCA diagnosis, and the researchers compared them to 104 age and gender-matching eye-free controlsEach visual symptom is associated with an ophthalmic diagnosis, which is re-evaluated by an ophthalmologistcompared to the control group, patients with visual symptoms had less fever (p-0.0006) and rheumatic polymyalgia (p-0.02) and lower levels of acute stage reactants (p-0.004)Prior to GCA diagnosis, patients described four visual symptoms: blurred vision (60 per cent of the patient), a sexual black hichea (18 per cent), multiple vision (13 per cent) and permanent vision loss (9 per cent)In 47 patients (45%), there was a pre-ischemic optic neuropathy (AION), followed by 15 patients (15%) with central retinal artery obstruction (CRAO)In 2 patients, both conditions existed at the same timeThere was no difference in delayed treatment of glucocorticoids in patients with or without visual symptoms (p-0.06)In 60 patients with initial AION and/or CRAO, 39 (65%) sustained blindness or severe vision impairment, although 45 (75%) received metastasis with methicillin vein (IV) shock therapyDespite the onset of treatment, 4% of patients with visual symptoms develop new ischemic events (all AION)the study observed that a quarter of GCA patients had eye damageAION is still associated with the worst vision prognosis, and IV-meth nylon shock therapy does not reduce the risk of blindness
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.